SCHEMBL19922665

SCHEMBL19922665

Cc1cn2cc(-c3nc(C(F)(F)F)n[nH]3)nc(Cc3ccccc3F)c2n1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.34
PDE5A O76074 1/20 0.34
PDE4A P27815 1/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
PDE1C Q14123 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRM5 P41594 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
AVPR2 P30518 1/20 0.30
AVPR1A P37288 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19922794 0.84 AR (0.34) ARKDM4EALDH1A1TP53SMN1; SMN2
Zagociguat SCHEMBL19922804 0.84 AR (0.34) ARPDE5APDE4APDE1APDE1B
SCHEMBL19922744 0.84 PDE5A (0.36) ARPDE5APDE4APDE1APDE1B
Zagociguat SCHEMBL21333483 0.83 PDE5A (0.35) ARPDE5APDE4APDE1APDE1B
Zagociguat SCHEMBL21332996 0.83 AR (0.34) ARPDE5APDE4APDE1APDE1B
SCHEMBL19922956 0.82 HDAC6 (0.36) ARPDE5APDE4APDE1APDE1B
Zagociguat SCHEMBL21332766 0.82 PDE5A (0.34) ARPDE5APDE4APDE1APDE1B
Zagociguat SCHEMBL21332963 0.82 PDE5A (0.33) ARPDE5APDE4APDE1APDE1B
Zagociguat SCHEMBL21332705 0.81 PDE5A (0.33) ARPDE5APDE4APDE1APDE1B
SCHEMBL23875659 0.80 AR (0.34) ARPDE5APDE4APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326761-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC (US) 2025-10-23 US disclosed
CN-117105939-A Fused bicyclic sGC stimulators 帝善多制药公司 2023-11-24 CN disclosed
US-11731977-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-08-22 US disclosed
US-11731977-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-08-22 US disclosed
US-11731977-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2023-08-22 US disclosed
EP-3872080-B1 FUSED BICYCLIC SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-08-16 EP disclosed
EP-3872080-B1 FUSED BICYCLIC SGC STIMULATORS CYCLERION THERAPEUTICS INC (US) 2023-08-16 EP disclosed
CN-109790167-B SGC stimulators 塞科里昂医疗股份有限公司 2023-06-20 CN disclosed
US-20220009937-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-13 US disclosed
US-20220009937-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-13 US disclosed
US-10472363-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2019-11-12 US disclosed
US-10472363-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2019-11-12 US disclosed
US-20190248794-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2019-08-15 US disclosed
US-20190248794-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2019-08-15 US disclosed
EP-3507291-A1 FUSED BICYCLIC SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-07-10 EP disclosed
WO-2018045276-A1 FUSED BICYCLIC SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
WO-2018045276-A1 FUSED BICYCLIC SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-03-08 WO disclosed
US-20180065971-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2018-03-08 US disclosed
US-20180065971-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2018-03-08 US disclosed
US-20180065971-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2018-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10472363-B2 SGC stimulators GUCY1A2, PRKG1, GMPS AR 4543/4885PDE5A 12/4885PDE4A 16/4885
US-20250326761-A1 sGC STIMULATORS GUCY1A2, PRKG1, GMPS AR 4543/4885PDE5A 12/4885PDE4A 16/4885
US-20180065971-A1 sGC STIMULATORS GUCY1A2, PRKG1, GMPS AR 4543/4885PDE5A 12/4885PDE4A 16/4885
US-20220009937-A1 sGC STIMULATORS GUCY1A2, PRKG1, GMPS AR 4543/4885PDE5A 12/4885PDE4A 16/4885
US-11731977-B2 SGC stimulators GUCY1A2, PRKG1, GMPS AR 4543/4885PDE5A 12/4885PDE4A 16/4885
US-20190248794-A1 sGC STIMULATORS GUCY1A2, PRKG1, GMPS AR 4543/4885PDE5A 12/4885PDE4A 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.